ICU Medical, Inc. Reports Third Quarter 2012 Results

October 15, 2012

Revenues grew 6.5% to a record $81.4 million

Diluted EPS increased 26% to $0.82

The Company Raises Full Year 2012 EPS Guidance Range and Lowers Full Year Revenue Guidance Range

SAN CLEMENTE, Calif., Oct. 15, 2012 (GLOBE NEWSWIRE) -- ICU Medical, Inc., (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical devices used in infusion therapy, oncology and critical care applications, announced today results for the third quarter and nine months ended September 30, 2012.

Third quarter of 2012 revenue increased 6.5% to a record $81.4 million, compared to $76.5 million in the same period last year. Net income for the third quarter of 2012 was $12.2 million, or $0.82 per diluted share, as compared to net income of $9.3 million, or $0.65 per diluted share, for the third quarter of 2011.

For the nine months ended September 30, 2012, revenue increased 3.8% to $234.2 million, compared to $225.7 million in the same period last year. Net income for the nine months ended September 30, 2012, was $28.9 million, or $1.98 per diluted share, compared to net income of $26.8 million, or $1.89 per diluted share, for the same period last year.

Scott Lamb, ICU Medical's Chief Financial Officer, said, "Our top line growth during the quarter was driven by increases in our infusion therapy, and oncology markets, which was partially offset by a decrease in critical care revenue and impact of the Euro currency translation during the quarter. Domestic sales were up 8.0%, while international sales grew 1.7%, compared to the same quarter a year ago. Our gross margins expanded 346 basis points year over year, reflecting positive product mix and more favorable peso exchange rates. As we continued to focus on cost efficiencies, we achieved solid operating margins of 21.5%, compared to 17.4% a year ago."

"We are confident our strong financial position and positive cash flow position us well for further investments in our product portfolio and expansion of our market presence," concluded Mr. Lamb.

Revenue by market segment for the nine months ended September 30, 2012 was as follows:

(dollars in millions)
Market Segment 2012 2011 Change
Infusion Therapy $159.6 $146.4 9.1%
Critical Care $42.4 $47.2 -10.2%
Oncology $21.0 $19.0 10.5%
Other $11.2 $13.1 -14.6%
  $234.2 $225.7 3.8%

The Company ended the third quarter with a very healthy balance sheet. As of September 30, 2012, cash, cash equivalents and investment securities totaled $204.3 million and working capital was $283.7 million. Additionally, the Company generated operating cash flow of $9.5 million for the third quarter of 2012.

Fiscal Year 2012 Guidance

Based on the current business trends, management is lowering its previously announced revenue guidance range for the full fiscal year of 2012. The new range is $315 million to $318 million, compared to the previous range of $318 million to $325 million. Management is raising its previously announced diluted earnings guidance range. The new range is $2.75 to $2.80 per share, compared to the previous range of $2.55 to $2.70 per share. Operating cash flow is expected to be in the range of $45 million to $50 million.

Conference Call

The Company will be conducting a conference call concerning its third quarter results today at 4:30 p.m. EDT (1:30 p.m. PDT). The call can be accessed at 877-303-6235, international 631-291-4837, conference ID 28589433. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's website at, clicking on the Investors tab, clicking on the Webcast icon and following the prompts. The webcast will also be available by replay.

About ICU Medical, Inc.

ICU Medical, Inc. (Nasdaq:ICUI) develops, manufactures and sells innovative medical technologies used in infusion therapy, oncology, and critical care applications. ICU Medical's products improve patient outcomes by helping prevent bloodstream infections, protecting healthcare workers from exposure to infectious diseases or hazardous drugs and monitor continuous cardiac output of critical care patients. The Company's complete product line includes custom infusion and monitoring systems, closed delivery systems for hazardous drugs, needleless I.V. connectors, catheters and cardiac monitoring systems. ICU Medical is headquartered in San Clemente, California. For more information, visit the Company's website at

 Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as ''will,'' ''expect,'' ''believe,'' ''could,'' ''would,'' ''estimate,'' ''continue,'' ''build,'' ''expand'' or the negative thereof or comparable terminology, and may include (without limitation) information regarding the Company's expectations, goals or intentions regarding the future, including, but not limited to, statements regarding the Company's being positioned for further investments in its product portfolio and expansion of its market presence and delivering value to shareholders and the statements under the heading ''Fiscal Year 2012 Guidance.'' These forward-looking statements are based on Management's current expectations, estimates, forecasts and projections about the Company and assumptions Management believes are reasonable, all of which are subject to risks and uncertainties that could cause actual results and events to differ materially from those stated in the forward-looking statements. These risks and uncertainties include, but are not limited to, decreased demand for the Company's products, increased competition from competitors, lack of continued growth or improving efficiencies and unexpected changes in the Company's arrangements with its largest customers. Future results are subject to risks and uncertainties, including the risk factors, and other risks and uncertainties, described in the Company's filings with the Securities and Exchange Commission, which include those in the Annual Report on Form 10-K for the year ended December 31, 2011. Forward-looking statements contained in this press release are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

ICU Medical, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(Amounts in thousands, except per share data)
 September 30,December 31,
Cash and cash equivalents  $ 127,524  $ 99,590
Investment securities 76,768 60,395
Cash, cash equivalents and investment securities 204,292 159,985
Accounts receivable, net of allowance for doubtful accounts of $1,146 at September 30, 2012 and $1,293 at December 31, 2011 53,010 43,571
Inventories 37,587 40,423
Prepaid income taxes 7,568 5,589
Prepaid expenses and other current assets 5,931 6,759
Deferred income taxes 4,220 4,081
Total current assets 312,608 260,408
PROPERTY AND EQUIPMENT, net 83,641 83,048
GOODWILL 1,478 1,478
INTANGIBLE ASSETS, net 10,423 11,419
   $ 412,907  $ 361,112
Accounts payable  $ 12,165  $ 13,251
Accrued liabilities 16,745 16,059
Total current liabilities 28,910 29,310
Convertible preferred stock, $1.00 par value Authorized—500 shares; Issued and outstanding—none
Common stock, $0.10 par value—Authorized—80,000 shares; Issued 14,855 shares at September 30, 2012 and December 31, 2011, outstanding 14,404 shares September 30, 2012 and 13,871 shares at December 31, 2011 1,486 1,486
Additional paid-in capital 62,255 56,796
Treasury stock, at cost—451 shares at September 30, 2012 and 984 shares at December 31, 2011 (17,009) (35,348)
Retained earnings 329,815 300,877
Accumulated other comprehensive loss (3,514) (3,234)
Total stockholders' equity 373,033 320,577
   $ 412,907  $ 361,112
(1) December 31, 2011 balances were derived from audited consolidated financial statements.
ICU Medical, Inc. and Subsidiaries
Condensed Consolidated Statements of Income
(Amounts in thousands, except per share data)
 Three months ended September
Nine months ended September
Net sales  $ 81,266  $ 76,317  $ 233,788  $ 225,316
Other 139 141 409 409
TOTAL REVENUE 81,405 76,458 234,197 225,725
COST OF GOODS SOLD 40,710 40,884 119,455 119,324
Gross profit 40,695 35,574 114,742 106,401
Selling, general and administrative 20,177 20,411 63,873 63,004
Research and development 2,988 1,877 8,410 6,420
Legal settlement (2,500)
Total operating expenses 23,165 22,288 72,283 66,924
Income from operations 17,530 13,286 42,459 39,477
OTHER INCOME 158 132 438 966
Income before income taxes 17,688 13,418 42,897 40,443
PROVISION FOR INCOME TAXES (5,500) (4,157) (13,959) (13,616)
NET INCOME  $ 12,188  $ 9,261  $ 28,938  $ 26,827
Basic  $ 0.85  $ 0.66  $ 2.04  $ 1.94
Diluted  $ 0.82  $ 0.65  $ 1.98  $ 1.89
Basic 14,321 13,932 14,153 13,826
Diluted 14,826 14,184 14,613 14,169
ICU Medical, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(Amounts in thousands)
 Nine months ended September 30,
Net income  $ 28,938  $ 26,827
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 14,262 13,687
Provision for doubtful accounts (143) 509
Provision for warranty and returns 291  —
Stock compensation 4,361 2,998
Loss (gain) on disposal of property and equipment 41 (57)
Bond premium amortization 1,660 801
Cash provided (used) by changes in operating assets and liabilities    
Accounts receivable (9,790) 1,575
Inventories 2,974 1,143
Prepaid expenses and other assets 792 (2,406)
Accounts payable (943) (272)
Accrued liabilities 682 (1,698)
Deferred revenue (254)
Prepaid and deferred income taxes (2,194) (6,802)
Net cash provided by operating activities 40,931 36,051
Purchases of property and equipment (13,208) (13,761)
Proceeds from sale of asset 10
Intangible asset additions (951)  —
Proceeds from insurance 2,781
Purchases of investment securities (78,534) (66,330)
Proceeds from sale of investment securities 60,452 26,935
Net cash used by investing activities (32,231) (50,375)
Proceeds from exercise of stock options 13,214 7,021
Proceeds from employee stock purchase plan 2,220 909
Tax benefits from exercise of stock options 4,002 3,682
Purchase of treasury stock (9,992)
Net cash provided by financing activities 19,436 1,620
Effect of exchange rate changes on cash (202) 793
CASH AND CASH EQUIVALENTS, beginning of period 99,590 78,850
CASH AND CASH EQUIVALENTS, end of period  $ 127,524  $ 66,939
CONTACT: ICU Medical, Inc.

         Scott Lamb, Chief Financial Officer

         (949) 366-2183


         ICR, LLC

         John F. Mills, Senior Managing Director

         (310) 954-1105